ADDF's Diagnostics Accelerator licenses SpeechDx dataset to Eli Lilly for Alzheimer's research
A short entry: a summary of the public record, checked against its sources, not yet read and analysed by Gianluca. How the register works
On 28 October 2026 the Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator announced that Eli Lilly and Company had licensed its SpeechDx dataset, a longitudinal collection of speech and biomarker data, to investigate the utility of speech as a tool for Alzheimer's research.
What happened
- The licensing was announced on October 28, 2026 by the ADDF's Diagnostics Accelerator (DxA).
- Lilly is the third organization to license SpeechDx, after Siemens Healthineers (announced May 1, 2025) and Callyope (announced September 30, 2025).
- SpeechDx was launched in 2023 by the DxA and is described as the ADDF's largest investment in AI to date.
- The study follows more than 2,000 participants over three years, pairing speech data with blood-based biomarkers, neuropsychological testing and MRI.
- Mark Mintun, group vice president of Neuroscience Research and Development at Eli Lilly, is quoted in the announcement; Isobel Coleman is cited as ADDF CEO and Niranjan Bose as Managing Director, Health and Life Sciences at Gates Ventures.
- The ADDF announcement does not disclose a licence fee, duration or exclusivity terms.
Who is involved
The Diagnostics Accelerator is a research initiative dedicated to accelerating the development of affordable and accessible biomarkers to diagnose Alzheimer's disease and related dementias.
2026 initiative total US$150M (parent ADDF program)
Eli Lilly and Company is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana.
Sources
- alzdiscovery.org — primary
- alzdiscovery.org — party background
- unite.ai — party background
- healthtechnologynet.com — party background
Announced 2026-10-28